INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 8 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 11,795,000 | $12,029 | 3.59% |
| Context Capital Management, LLC | 22,730 | $17,422 | 1.28% |
| OAKTREE CAPITAL MANAGEMENT LP | 8,395,000 | $6,300,448 | 0.07% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $170,303 | 0.04% |
| Calamos Advisors LLC | 5,000,000 | $3,784,450 | 0.02% |
| FRANKLIN RESOURCES INC | 21,000,000 | $15,760,500 | 0.01% |
| Russell Investments Group, Ltd. | 1,706,000 | $1,295,607 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
This page lists INTERCEPT PHARMACEUTICALS IN's shareholders in Q4 2022. To view INTERCEPT PHARMACEUTICALS IN's shareholder history, click here.